Wee1

Catalog No.	Product Name	Information	Product Use Citations
S1525	Adavosertib (MK-1775)	Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.	Sci Adv, 2022, 8(5):eabk0221 J Exp Med, 2022, 219(1)e20210789 Cell Rep, 2022, 38(3):110261
S8148	PD0166285	PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). PD0166285 is also a novel G2 checkpoint abrogator. PD0166285 induces apoptosis.	Cancer Sci, 2020, 112(1):133-143 Nature, 2019, 10.1038/s41586-019-1607-3 Nature, 2019, 574(7777):268-272
S1525	Adavosertib (MK-1775)	Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.	Sci Adv, 2022, 8(5):eabk0221 J Exp Med, 2022, 219(1)e20210789 Cell Rep, 2022, 38(3):110261
S8148	PD0166285	PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). PD0166285 is also a novel G2 checkpoint abrogator. PD0166285 induces apoptosis.	Cancer Sci, 2020, 112(1):133-143 Nature, 2019, 10.1038/s41586-019-1607-3 Nature, 2019, 574(7777):268-272